Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Gentex Corporation delivered a mixed 2025, with Q4 results buoyed by its Vox acquisition and improved core profitability, while tariffs on China exports continued to pressure sales. The automotive tech supplier provided a roadmap focused on advanced mirrors, sensing, and new electrochromic applications like dimmable visors.
Apple's first-quarter revenue surged 16% to $143.8 billion, powered by what CEO Tim Cook called "staggering" demand for the iPhone 17, which generated over $85 billion in sales and fueled explosive growth in China.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
Alibaba's logistics arm Cainiao and autonomous driving firm Zelos Technology have merged to form a standalone robovan business, valued at approximately $2 billion. The move signals a strategic push into automated delivery solutions within China's competitive e-commerce landscape, as the tech giant seeks new growth engines beyond its core operations.
Hong Kong tycoon Li Ka-shing and his conglomerate CK Hutchison have been tied up in global US-China rivalry since announcing a controversial $19 billion sale of strategic ports in Panama last year.Beijing authorities intensified pressure on CK Hutchison last year, repeatedly criticising the conglomerate's sale of its Panama Canal ports.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
Nissan Motor Co. faced a 4.4% decline in global sales for 2025, with a sharper 6.7% drop in December, as weakness in key markets like China and Europe offset gains in North America.
British Prime Minister Keir Starmer arrived in Shanghai Friday with over 50 business leaders, aiming to deepen UK-China commercial ties. The visit, the first by a UK premier in eight years, comes against a backdrop of renewed US skepticism over Western engagement with Beijing.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
Apple's fiscal first-quarter earnings shattered expectations with $143.8 billion in revenue, fueled by unprecedented demand for the iPhone 17 in Greater China. While services hit new highs, the company flags memory cost pressures and supply constraints for the coming quarter.
In a volatile market, certain low-priced Asian stocks are drawing attention not just for their valuation, but for underlying financial strength. We examine three such companies—from healthcare in New Zealand to property services in Greater China—that defy the typical 'penny stock' stereotype with solid fundamentals.
Apple's Q1 earnings smashed expectations, fueled by surging iPhone sales and robust performance in China. While CEO Tim Cook's operational prowess is undeniable, the company's muted AI strategy and reliance on a Google partnership left investors wanting more.
A disappointing full-year EBITDA performance from its crucial Macau operations triggered a sharp sell-off in Las Vegas Sands stock, underscoring the lingering challenges facing the gaming giant in the wake of China's regulatory crackdown.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
Apple's fiscal Q1 2026 results, fueled by "staggering" demand for the iPhone 17, delivered record revenue and a dramatic turnaround in China, silencing critics and reigniting growth.
Business Facilities magazine has named North Carolina its 'State of the Year' for business climate and economic development, the state's third such win in six years, following a surge of multi-billion dollar investments from tech and manufacturing giants.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
Under new CEO Michael Leiters, Porsche is reportedly considering axing its planned all-electric 718 Boxster and Cayman line. The potential move, driven by development hurdles and soaring costs, signals a strategic recalibration as the automaker grapples with a sales slowdown in China and the financial weight of revising its EV roadmap.
Amidst shifting economic currents in Asia, a class of smaller companies—often overlooked as 'penny stocks'—is attracting attention for their distinct financial profiles and niche market positions. We analyze three such firms with market capitalizations below US$200 million.
